The share price of Aeterna Zentaris (TSX: AEZ) fell more than half after the Canadian firm announced its Phase III study of Zoptrex (zoptarelin doxorubicin) had failed.
The company, which has been developing Zoptrex to treat women with endometrial cancer, said no statistically-significant increase in survival rates in the test group was observed.
Shares in co-development partner Ergomed (LSE: ERGO) are trading about 4% lower in London today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze